Buffington Mohr McNeal’s Quest Diagnostics DGX Stock Holding History

Buffington Mohr McNeal’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-967	Closed	-$87K	–	164
2019 Q1	$87K	Buy	+967	New	+$83.8K	0.03%	157
2018 Q4	–	Sell	-1,967	Closed	-$212K	–	116
2018 Q3	$212K	Hold	1,967	–	–	0.07%	115
2018 Q2	$216K	Buy	+1,967	New	+$205K	0.08%	116
2017 Q3	–	Sell	-1,967	Closed	-$219K	–	125
2017 Q2	$219K	Sell	1,967 -433	-18%	-$45.8K	0.09%	129
2017 Q1	$236K	Hold	2,400	–	–	0.1%	103
2016 Q4	$221K	Hold	2,400	–	–	0.08%	115
2016 Q3	$203K	Hold	2,400	–	–	0.09%	113
2016 Q2	$195K	Hold	2,400	–	–	0.09%	117
2016 Q1	$171K	Buy	+2,400	New	+$161K	0.08%	131

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Buffington Mohr McNeal's DGX Position: Q2 2019 in Review

Buffington Mohr McNeal sold out of Quest Diagnostics (DGX) in Q2 2019, closing a stake of 967 shares — an estimated $87K sold.

Buffington Mohr McNeal first reported a position in DGX in Q1 2016 and held it in 9 quarters. The position peaked at $236K in Q1 2017. 654 funds tracked by Wall St. Rank hold DGX as of Q2 2019.

Buffington Mohr McNeal reported no remaining Quest Diagnostics position as of Q2 2019 after selling out during the quarter.
Buffington Mohr McNeal sold 967 Quest Diagnostics shares in Q2 2019, an estimated $87K.
Buffington Mohr McNeal first reported a position in Quest Diagnostics in Q1 2016 and held it in 9 quarters.
Buffington Mohr McNeal's Quest Diagnostics position peaked at $236K in Q1 2017.
654 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2019.

Based on Buffington Mohr McNeal's 13F filing for Q2 2019, filed 31 Jul 2019.